Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes    Leukemias    Solid Tumours    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Roles of tetraspanin proteins in cell and tumor biology

Pedro A. Lazo

Programa de Oncología Translacional, Instituto de Biología Molecular y Celular del Cáncer,

Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, E-37007, Spain

 

September 2008

 

 

 

Corresponding author:
Dr. P. A. Lazo, IBMCC-Centro de Investigación del Cáncer, CSIC- Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.
Tel: 34 923 294 804
Fax: 34 923 294 795
Email: plazozbi@usal.es

 

Tetraspanin protein family and its web

In the human proteome, there are thirty-three proteins composing the tetraspanin (Tspan) family, which are a group of highly hydrophobic membrane proteins defined by their structural characteristics (Figure 1). Tetraspanins have four transmembrane domains with short intra-cytosolic N- and C-terminal regions, and two extracellular (EC) loops (Tarrant et al., 2003). The large EC2 loop has distinctive characteristics, such as a conserved CCG motif and conserved cysteines permitted the identification of a protein signature (Shoham et al., 2006), so that three tetraspanin subgroups are identified based on their folding patterns (Seigneuret et al., 2001). The hydrophobic transmembrane regions also contain conserved polar residues (Figure 1). The short C-terminal region is likely to provide a link to intracellular signaling molecules (Stipp et al., 2003).

Figure 1

Tetraspanin biology should be considered as a compartmentalized system (Levy and Shoham, 2005). The tetraspanin web is a complex containing several tetraspanins interacting among themselves on the membrane, forming a core that can interact with many different molecules; thus the composition of individual complexes is very likely to determine different biological effects (Lazo, 2007), making it a compartmentalized system. Most of the knowledge on this web was obtained from a small number tetraspanins, mainly CD9, CD81, CD82 and CD151 (Hemler, 2005). CD53, CD63 and CD37 have also been detected in complexes, and the remaining tetraspanins have not been studied in this context. Their combination permits a large variability, forming platforms for associated proteins (Levy and Shoham, 2005), which is very likely to be more important biologically than individual components. These proteins are expressed in most cell types (Wright et al., 2004), but most of the functional information has been obtained in cells of the hematopoietic system or epithelial cells (Hemler, 2005).

The tetraspanin partners in the web

Individual tetraspanin proteins can interact with several different types of proteins (Levy and Shoham, 2005), most of which play a receptor role, or alternatively couple receptors to signalling pathways. These interacting proteins range from membrane receptors, adhesion molecules to signal transduction molecules (Table 1).

 

Some of these protein-protein interactions are restricted to a specific tetraspanin protein. The combination of tetraspanins and the proteins listed in Table 1 suggests there are multiple different combinations between tetraspanins and their associated proteins. Although some combinations are specific, clearly many others remain to be identified. This heterogeneity of tetraspanin interactions with a variety of membrane proteins is likely to determine the biological role of tetraspanins as costimulatory molecules.

Interactions with integrins, relevance to cellular adhesion

Individual interactions between tetraspanins and integrins but are the most extensively studied interaction, but their web context was not considered (Berditchevski, 2001). However, despite the relevance of integrins in processes such as adhesion to extracellular matrix, cell motility, invasion and angiogenesis (Janes and Watt, 2006; Watt, 2002), the functional consequences of these interactions have received relatively little attention, perhaps because no tetraspanin ligand has so far been identified.
The main integrin found associated are those containing the β1 chain, mostly combined with α3, α4 or α6, in most cell types; and less frequently α2 and α5 (Berditchevski, 2001). The β1 chain is a major component of the attachment to the extracellular matrix (Hemler and Lobb, 1995), and signals by the activation of the integrin-linked kinase (ILK) (Dedhar, 2000). Some of these interactions have been reported for a specific tetraspanin, as is the case of α1β1 with CD9, but others as α4β1 were detected associated to CD9, CD53, CD81, CD82 or CD151. A direct interaction has only been demonstrated for CD151-α3β1 (Yauch et al., 2000). In general it can be concluded that one α integrin can bind to more than one type of tetraspanin. Although the β chain also contributes to the interaction, as exemplified by CD151 that interacts with α6β1 and α6β4 (Berditchevski et al., 1996). These CD151-integrin interactions strengthened the attachment to the extracellular matrix (Nishiuchi et al., 2005), but if they are functionally different depending on cell type, lymphoid or epithelial, is not known.
The tetraspanin complex with integrins is in low affinity conformation, and changes in affinity do not alter the integrin-tetraspanin interaction and integrin activation does not affect their tetraspanin interaction (Berditchevski, 2001), but tetraspanins appear to affect the post-ligand effects such as modulating actin dynamics, reflected in migration and cell adhesion properties. The tetraspanin-integrin complexes a might provide spatial cues for cellular polarization (Yanez-Mo et al., 2001).

Growth factor receptors and other membrane receptors

Growth factor receptors is a major group of Tspan interacting proteins, the receptors belong to different types (Table 1) including those with immunoglobulin domains, particularly those of the EWI family, but without considering their supramolecular organization, which can affect the magnitude or specificity of their effects and the functional consequences of any of them are unknown.
Regarding growth factor receptors with tyrosine-kinase activity, CD9 interacts with the HB-EGF receptor (Lagaudriere-Gesbert et al., 1997) and. c-Met/HGF-R (hepatocyte growth factor receptor), the receptor for the scatter factor (SF) or HGF that is implicated in epithelial-mesenchimal transition, a fundamental process in the dissemination of tumor cells (Trusolino and Comoglio, 2002) c-Met interacts with CD82 (Sridhar and Miranti, 2006). The interaction of the ganglioside GM2 with the CD82-c-Met inhibits its cross-talk with integrin signaling, and reduces c-Met activation signal (Todeschini et al., 2008). In epithelial cells CD9 interacts with epithelial cell adhesion molecule (Ep-CAM) (Le Naour et al., 2006). But the functional consequences of interactions between different tetraspanins and cadherins have not yet been performed.
It can be concluded that our knowledge on tetraspanin effects on signals initiated in interacting growth factor receptors is rather limited.

Membrane proteins

Proteins of the HLA family, both class II and class I, constitute a major group of proteins associated with tetraspanins (Lagaudriere-Gesbert et al., 1997; Szollosi et al., 1996).The most characterized is the interaction with class II antigens, but class I have also been detected (Berditchevski and Odintsova, 2007; Engering and Pieters, 2001; Szollosi et al., 1996), particularly with CD53, CD37 or CD81 (Angelisova et al., 1994). However, if tetraspanin proteins modulate signals or functions mediated by these HLA antigens has not been characterized, but are likely to affect antigen presentation (Berditchevski and Odintsova, 2007). In dendritic cells the lateral interaction between CD9 and MHC class II antigen facilitated T-cell activation (Unternaehrer et al., 2007). It will be important to determine their functional consequences in tumor cells were HLA antigens expression is frequently downregulated to facility immune evasion.

Intracellular signaling molecules

Tetraspanins are considered as molecular facilitators because they participate, or modulate, several signaling and biological processes (Maecker et al., 1997), detected in very heterogeneous cell types, but their implication is clear; tetraspanins can influence intracellular signaling, directly or indirectly, and thus can modulate signals initiated in other membrane receptors that are present on the Tspan web. Due to the lack of any known ligand, most signals have been studied using specific monoclonal antibodies. In this regard CD9, CD82, CD81 and CD53 are the best-characterized antigens (Boucheix and Rubinstein, 2001). In this context CD9, CD82, CD81 and CD53 are the best-characterized antigens (Boucheix and Rubinstein, 2001). Among signals detected in response to tetraspanin antigen ligation by monoclonal antibodies were calcium mobilization by CD9, CD53, CD81 or CD82, protein kinase C activation, increased levels of diacylglycerol, activation of phosphatidylinositol 3-kinase (PI 3K) and phospholipase Cγ (Boucheix and Rubinstein, 2001).
Another component of tetraspanin signaling is a consequence of direct physical interaction between some tetraspanins, such as CD151, and type II phosphatidylinositol 4-kinase (PI 4K); in this case the tetraspanin functions as the connector between the associated integrin and the PI 4K molecule (Berditchevski et al., 1997; Claas et al., 2001). Only some tetraspanins, CD9, CD63, CD81, A15 and CD151 are associated with PI 4K, but not others such as CD82, CD53 or CD37; and their interaction does not require previous binding to an integrin, therefore it may be mediated by a not yet identified protein, and will have functional consequences depending on the pattern of expression and integration in the tetraspanin web in different cell types. All these effects have been reported in very heterogeneous cell types. But the implication is clear; tetraspanins can influence intracellular signalling, directly or indirectly, and thus can modulate signals initiated in other membrane receptors.
CD53 ligation activates protein kinase C (PKC) (Barcia et al., 1996; Bosca and Lazo, 1994; Lazo et al., 1997); and later it was demonstrated that following cell stimulation, PKC binds to the intracellular side of CD9, CD53, CD81, CD82, and CD151 (Zhang et al., 2001), this bound PKC was able to phosphorylate the integrin α3 subunit interacting with CD151. Also CD53 ligation could transiently activate the c-jun NH2-terminal kinase (JNK) and c-Jun dependent transcription (Yunta et al., 2002). In renal mesangial cells the ligation of CD53 induced a proliferative response mediated by the extracellular-regulated kinases, ERK1 and ERK2 (Yunta et al., 2003). Furthermore, CD53 and CD63 have been found associated with a tyrosine phosphatase (CD45) that dephosphorylates lck (Carmo and Wright, 1995).

The tetraspanin web is regulated by lipids

Palmitoylation determines the formation of cholesterol rich microdomains

Membrane proteins can be covalently modified by palmitoylation that can control their association and organization in different cellular membranes. The tetraspanins CD9, CD37, CD53, CD63, CD81, CD82 and CD151 are palmitoylated molecules (Charrin et al., 2002), that occurs in intracellular cysteines; and which is a requirement for their association with cholesterol complexes (Charrin et al., 2003). The assembly of the tetraspanin web is started in the Golgi, where homodimers, as well as heterodimers, of CD9, CD81, or CD151, constituting intermediate building blocks in the assembly of the tetraspanin web (Kovalenko et al., 2004). Palmitoylated tetraspanins appeared to be important for assembly of the web, favoring association with other tetraspanins and their associated proteins (Berditchevski et al., 2002; Yang et al., 2002). Palmitoylated CD9, CD81, and CD63 colocalize with palmitoylated integrin ß4, which promoted the incorporation of CD151 to these tetraspanin complexes (Yang et al., 2004). There are two types of complexes, those with palmitoylated tetraspanins that facilitate their association with integrins and integration in cholesterol-rich fractions, and those non-palmitoylated tetraspanins that are accessible to binding with different signaling molecules, such as 14-3-3, p130 (CAS) or EWI proteins among others. These two alternative signaling complexes are summarized in Fig.2.

Figure 2

Palmitoylation of CD9 promotes interaction with integrins and association with other tetraspanins, CD81 and CD53. Mutations in all palmitoylation residues CD9 (Charrin et al., 2002) or CD151 (Yang et al., 2002) resulted in a more diffuse distribution and prevented their association with cholesterol. Un-palmitoylated CD9 is freer and has an enhanced binding to EWI-2 and EWI-F (Yang et al., 2006). The loss of palmitoylation did not affect spreading on extracellular matrix, but these cells have a larger number of focal adhesions, and an increase in adhesion-induced phosphorylation of Akt, without affecting activation of FAK or ERK1/2 (Berditchevski et al., 2002).
Palmitoylation also controls the association between tetraspanins and intracellular signaling molecules. In these complexes, tetraspanin ligation increased phosphorylation of signaling molecules such as vav, and effect lost by treatment with cholesterol disrupting detergents (Charrin et al., 2003). In B-cells the coligation of the B-cell receptor (BCR) with CD19/CD21/CD81 promoted CD81 palmitoylation and stabilization of the complex within a cholesterol rich fraction (Cherukuri et al., 2004).
CD82 palmitoylation is necessary for mobility and invasion of PC13 cells, and loss of palmitoylation resulted in abolishment of these properties, and in regaining interaction with the p130 (CAS)-CrkII signaling complex (Zhou et al., 2004), also detected in CD9 (Yang et al., 2004).
Palmitoylation was regulated by the cellular redox state, and under oxidative stress palmitoylation is inhibited favoring signaling by 14-3-3 adaptor proteins (Clark et al., 2004), thus not palmitoylated CD81 was constitutively bound to 14-3-3 protein, a serine/threonine binding protein (Clark et al., 2004).

Gangliosides can regulate the composition of the tetraspanin web

Gangliosides are complex glycolipids which contain a branched chain of as many as seven sugar residues. Several specific interactions of gangliosides with tetraspanins have been reported. Thus GM3 ganglioside preferentially interacts with CD9 (Kawakami et al., 2002; Mitsuzuka et al., 2005) and CD81 (Toledo et al., 2004), reducing MAPK activation initiated in FGFR (Toledo et al., 2004). GM3, promotes the association of CD9 with the α3 integrin (Kawakami et al., 2002) or &alpha5; inhibiting cell motility (Miura et al., 2004). The GM2 ganglioside is mainly associated with CD82 (Odintsova et al., 2006; Todeschini et al., 2008), and GD2/GD3 gangliosides interacting with CD151 (Thorne et al., 2007) and CD82 inhibited cell motility (Todeschini et al., 2008).

Dynamics of tetraspanin microdomains: cell-specific complexes

The web assembly of tetraspanins and their specific interactions can be interpreted within the general framework of the dynamics of a complex with the potential for a very high functional heterogeneity (Fig.2). In this system there is a double level to increase complexity, the participation of the tetraspanins in the core, and the type and number of associated proteins. Thus diversity in the combination of proteins permits a very large flexibility which can determine functional differences depending on cell type. Therefore, tetraspanin complexes in specific cell types can be very different despite sharing several of their components. In that way the association of tetraspanin-membrane receptor may exist either as isolated complexes on cell surfaces, or forming part of a larger tetraspanin-core complex. Thus, the association-dissociation kinetics represents an important level of regulation, where palmitoylation and redox state play a major role, but these properties have not yet been characterized in detail in any system. Initiation of cell signals is very likely to be different if activated by either free molecules, in heterodimers, or a larger complex, such as the tetraspanin web.

Contribution of Tetraspanins to tumor biology: cell adhesion and motility

CD151. CD151 is mainly localized to the basal and lateral junctions of endothelial cells (Berditchevski and Odintsova, 1999) and blocking antibodies increased their adhesion to the ECM and reduced their rate of invasion in collagen gels (Yanez-Mo et al., 1998). In migrating ketarinocytes and breast cancer cells CD9, CD81, CD151 were involved in transient interactions with the substrate before a more stable interaction could be formed by attachment structures due to lamellopodia formation (Penas et al., 2000). These structures were both did not contain elements of the cytoskeleton, and colocalized with MARCKS, which are substrates of PKC that regulates cytoskeleton reorganization during migration (Berditchevski and Odintsova, 1999). In human skin, CD151 was clustered at the basal cell colocalizing with laminin 5 (Lagaudriere-Gesbert et al., 1997; Yamada et al., 2008) connecting focal adhesion with actin filaments as part of hemidesmosomes (Sterk et al., 2000). In polarized epithelial cells, CD9, CD151 and CD81 also localize with cadherins at lateral cell-cell contacts although the effect of antibodies is cadherin-independent. Overexpression of CD151 resulted in increased motility, and enhanced expression of matrix metalloproteinase-9 (MMP-9) and invasiveness (Hong et al., 2006); probably as a result of activating pathways mediated by small GTPases (Shigeta et al., 2003). CD151 knock-down in primary melanocytes resulted in a loss of motility (Garcia-Lopez et al., 2005), effects that are reversed by CD151 reexpression (Winterwood et al., 2006). The dissociation of CD151 from laminin-binding integrins permitted migration of epithelial cells (Chometon et al., 2006).These data on signaling and motility clearly implicate CD151 in cell adhesion and dissemination. The blocking of CD151 with an antibody is able to prevent tumor intravasation and metastasis (Zijlstra et al., 2008).

CD82. CD82 functions as a link between the actin cytoskeleton and membrane raft domains, inducing stable adhesion, spreading and development of membrane extensions. CD82 effects on actin polymerization depend on its association with the ECM and involves src kinases, Vav1, and p56 lck (Delaguillaumie et al., 2002; Lagaudriere-Gesbert et al., 1998). The depletion of gangliosides also destabilizes CD82 complexes (Ono et al., 1999), reducing interaction with CD151 and increasing the interaction with EGFR (Odintsova et al., 2006) and c-Met (Todeschini et al., 2007). All these effects are severely affected by cholesterol depletion (Delaguillaumie et al., 2004).Overexpression of CD82 might contribute to tumor invasion by inhibiting the cross-talk between integrins and Met and src activation and phosphorylation of its downstream targets, p130Cas and FAK (Sridhar and Miranti, 2006; Zhang et al., 2003). Inhibition of c-Met or Src reduced invasion to the same extent as CD82 e(Sridhar and Miranti, 2006). High levels of CD82 correlate with a lower invasion potential in prostate (Zhang et al., 2003), lung (Adachi et al., 1996), esophageal cancer (Uchida et al., 1999) and by its overexpression in multiple myeloma cell lines (Tohami et al., 2007).
CD82 surface expression is up-regulated by several cytokines such as interleukin-1 beta (IL-1 ß), IL-4, IL-6 , IL-13, interferon-gamma, tumor necrosis factor-a antigen (Lebel-Binay et al., 1995b). Co-ligation of CD82 and Fc receptors induces an increase in calcium level mediated by phospholipase C (PLC)-induced PtdIns(1,4,5)P3 second messenger followed by a more stable change, linked to extracellular calcium entry (Lebel-Binay et al., 1995b). In Jurkat cells stimulated of with anti-CD82 and anti-CD3 mAbs implicates different transcription factors such as NF-AT, AP-1, and NF-κB (Iwata et al., 2002), with increased production of IL-2; and cells become adherent developing dendritic extensions, cell proliferation is arrested(Lebel-Binay et al., 1995a).
The interaction of Cd82 with DARC (duffy antigen receptor for chemokines) a in on prostate and endothelial cells has been identified as a binding partner of CD82 cells (Bandyopadhyay et al., 2006), makes them to enter senescence (Iiizumi et al., 2007).

CD9. The association of CD9 with the transmembrane region of TGF-α resulted in the induction of EGFR activation and cellular proliferation (Shi et al., 2000). Also, the metalloprotease ADAM10 promotes the association of CD9 with HG-EGF (Yan et al., 2002). But CD9 has been associated with control of cell motility. Functionally antibodies anti-CD9 inhibited transmigration of melanoma cells (Longo et al., 2001). In primary melanocytes where reduction of CD9 by siRNA resulted in loss of motility (Garcia-Lopez et al., 2005). Cell motility dependent on binding to laminin-5 is inhibited by the interaction of CD9 with the GM3 ganglioside (Kawakami et al., 2002). All these data suggested that CD9 as well as CD81 loss are likely to promote tumor dissemination. In agreement with this potential role, an inverse correlation between CD9 level and invasiveness has been reported in melanomas (Si and Hersey, 1993), breast cancer (Huang et al., 1998), oral squamous cell carcinomas (Kusukawa et al., 2001), ovarian carcinoma (Houle et al., 2002), and cervical carcinomas (Sauer et al., 2003b).

CD81. The ligation of CD81 initially had an antiproliferative effect, and regulated the intracellular thiol levels (Schick et al., 1993), forming part of the CD19/CD21 signaling complex on B-cells (Behr and Schriever, 1995). CD81 and CD151 tetraspanin molecules are components of the endothelial lateral junctions implicated in the regulation of cell motility, either directly or by modulation of the function of the associated integrin heterodimers (Yanez-Mo et al., 1998); and CD81 was associated with adhesion and motility in lymphocytes (Levy et al., 1998). The link between CD81 and the actin cytoskeleton seems to be mediated by EWI-2 and EWI-F (Sala-Valdes et al., 2006). CD81 overexpression reduces viability and motility in multiple myeloma cell lines (Tohami et al., 2007).

CD63. CD63 antigen is mostly detected at a very high concentration in endosomal particles; but it is also presented on cell surfaces. The C-terminal intracellular region of CD63 interacts with the PDZ domain of syntenin-1, a molecule that is implicated in regulation of endocytosis and slows down CD63 internalization (Latysheva et al., 2006). CD63 expression on cell surface affects tumor dissemination. The loss of CD63 was the first tetraspanin to be related with a very high invasive potential in melanomas, where an inverse correlation between CD63 levels and metastatic potential was identified (Hotta et al., 1988; Hotta et al., 1989), and its reexpression in melanoma cells reduced its invasion potential (Radford et al., 1995). A similar correlation has been reported in a colon carcinoma cell line (Sordat et al., 2002).

CD53: Radioresistance and effects on redox state. The CD53 ligation antigen with specific antibodies stimulates several processes such as the induction of nitric oxide synthase (Bosca and Lazo, 1994) in macrophages, homotypic cell adhesion in B-cell lymphomas (Lazo et al., 1997), or DNA synthesis in mesangial cells (Yunta et al., 2003), all of them on PKC activation. Part of the signal is also transmitted by the JNK system and has a protective effect on apoptosis in Jurkat cells (Yunta and Lazo, 2003).
CD53, CD82 and CD81 interact with gamma-glutamyl transpeptidase (GGT) a regulator of the intracellular redox state by modulating level of glutathione (Nichols et al., 1998). This is a very interestingly observation because the mechanism by which cells are killed by radiation therapy is based on its ability to generate free radicals in the cell; and is therefore strongly dependent on the intracellular redox state. Very high overexpression of CD53 is one of the main markers of radioresistant cells (Voehringer et al., 2000), resulting in an increase in the intracellular level of glutathione, which has anti oxidant properties and thus counteracts the radiation effect facilitating cell survival (Voehringer et al., 2000).

Patterns of tetraspanin protein expression in normal and stem cells

Tetraspanin surface expression in hematopoietic cells

The only overall picture of tetraspanin surface expression has been obtained in human B-cell maturation, in which the relative surface levels of six tetraspanins (CD9, CD37, CD53, CD63 and CD81), and their interacting proteins (CD19, CD21, and HLA-DR) was determined (Barrena et al., 2005b). This study identified three different combinations based on developmental stage: I) early bone marrow (BM) CD10+ B-cell precursors have high levels of CD81 and CD9 and relatively very low level of CD53, and negativity for CD37; II) mature/peripheral B-lymphocytes (CD10-) there is down-regulation of CD9/CD81 and up-regulation of CD53/CD37; III) in plasma cells that have passed through secondary lymphoid tissues and reentered the BM there is CD9 re-expression and CD37 down-regulation, but maintain the CD53 expression. These distinct patterns of tetraspanin expression may reflect the occurrence of different cellular interactions and homing properties during B-cell maturation. (Barrena et al., 2005b).
Although precursors of lymphoid cells express relatively higher levels of CD9, they also express CD53 and CD63 intracellularly located in endosomes, two proteins that in CD133+ stem cell population are distributed asymmetrically (Beckmann et al., 2007), a hallmark of stem cells, but its significance is unknown.

Tetraspanin proteins in epithelial cells

A systematic approach to detect six tetraspanin proteins, CD9, CD37, CD53, CD63, CD81, and CD82, in the gastrointestinal (GI) tract has been performed. Two of them, CD9 and CD82 were expressed at similarly high levels throughout the GI tract, from esophagus to colon. CD63 expression was more restricted, ranging from distal stomach to colon. CD81 was detected only in basal layers of the esophagus. CD53 was barely detected and no expression of CD37 was observed (Okochi et al., 1999). These differences suggest that the organization of the tetraspanin web can present major variations depending on its localization in the GI; but their functional significance is not known.
Tetraspanin proteins have also been used to attempt to identify epithelial precursor cells in the airway tract, which is severely damaged in diseases such as cystic fibrosis. In the basal cells of the trachea there is compartment of stem and transit amplifying cells. A marker of early stages is the detection of CD151 in combination with TF (Tissue factor) antigens. Therefore, tracheal cells positive for CD151/TF were able to proliferate and reconstitute a fully differentiated epithelium in rat with epithelium-denuded trachea. These cells were also positive for telomerase activity, which is considered a marker for the transit amplifying population. Cells of the columnar epithelium, CD151/TF negative were unable to proliferate or reconstitute the epithelium and have no telomerase activity. These data suggest that adult basal cells, CD151 positive, are present in the amplification compartment of the epithelium and have some regenerative potential (Hajj et al., 2006). It is not known if in other epithelial cells the situation is similar.
In the basal layer of normal squamous cervical epithelium there is a very high expression of CD9; which is down-regulated in squamous cervical carcinomas correlating with stage, but surprisingly as the tumor progresses there is a re-expression of CD9 as it becomes more vascularized, what might be an important element to permit tumor dissemination (Sauer et al., 2003b), and might reflect an interaction with vascular cells not yet identified.

Tetraspanins in human cancer

Most the information on expression of multiple tetraspanin proteins is a consequence of the information obtained using expression microarray in the analysis of different types of human cancer. These studies provide information on two aspects, the antigens expressed based on a given phenotype, and the relative change in the pattern as a function of differentiation or tumor phenotype, which indicate that they are functionally different.

Tetraspanin proteins in B-cell malignancies

The cell surface expression of four tetraspanin antigens and associated proteins has been studied in sixty-seven cases of B-cell malignancies (Barrena et al., 2005b). Hierarchical clustering analysis of flow cytometry immunophenotypic data showed a good correlation between the tumor differentiation stage and the pattern of tetraspanin expression (Barrena et al., 2005b). Mature/peripheral B-cell leukemias and lymphomas expressed high levels of CD37 and CD53; while those derived from BCP-ALL (acute lymphocytic leukemia), and clonal plasma cells (PC) coexpressed CD9 with either CD81 or CD53, respectively. Despite these phenotypic similarities, variable levels of expression of one or more of these proteins were frequently expressed and of these phenotypic aberrations were common to most patients within a specific disease group. The differences in the pattern of tetraspanin surface expression can be used to discriminate two different lymphomas in an individual patient (Barrena et al., 2005a). In B-CLL, the pattern of expression of CD9 and CD53 tetraspanins was associated with the pattern of in vivo tissue involvement. Thus, abnormally high reactivity for CD53 was associated with greater PB and lymph node infiltration. Previously it was demonstrated that ligation of CD53 antigen protects lymphoid cells from apoptosis (Yunta and Lazo, 2003), an important property for mature/peripheral memory lymphocytes. Therefore, overexpression of CD53 could render B-CLL (chronic lymphocytic leukemia) cells more adapted to survive in peripheral blood (PB) and lymph nodes. In contrast, reduced CD9 expression on B-CLL cells has been associated to a higher bone marrow (BM) involvement. CD9 also functions as a motility/migration brake (Ono et al., 1999), and this might explain the correlation detected between CD9 expression and the pattern of BM involvement.
In multiple myelomas (MM), there is CD9 expression in non active MM, while in active and aggressive MM there is an epigenetic silencing of CD9 gene expression (De Bruyne et al., 2008).

Tetraspanin proteins in carcinomas

Information on expression in carcinomas is derived mostly or from gene expression arrays and from determining few protein antigens; and functional information has been obtained from tumor cell lines. Tetraspanins have received little attention in human carcinomas but some information is emerging form three different lines of work.
The alternative expression of some tetraspanin antigens permits the identification of subgroups in different types of human cancer. The coordinated expression of tetraspanin initially identified in B-cells (previous section) appears to be more general. In kidney cancer, high expression of CD53 and CD37 inversely correlated with respect to CD9 expression (low) in conventional renal cell carcinomas of clear cells and in papillary carcinomas, but not in other types such as granular carcinomas in which CD9 expression is very high (Higgins et al., 2003). Also, in melanomas there is no CD53 and CD37 expression and express varying levels of CD9, the latter is inversely correlated with metastatic potential (Si and Hersey, 1993), a pattern consistent with a higher probability of infiltration in lymph nodes (Barrena et al., 2005b).
The loss of CD9 antigen has been correlated with higher motility and metastatic potential of tumor cells from lung (Higashiyama et al., 1995), esophageal (Uchida et al., 1999), oral (Kusukawa et al., 2001), ovarian (Houle et al., 2002), cervical (Sauer et al., 2003b), gastric (Hori et al., 2004) carcinomas. In the basal layer of the normal squamous epithelium of the uterine cervix CD9 is strongly expressed, but in invasive carcinomas is downregulated. However in some areas there is a re-expression of CD9 that were correlated with lymphangiosis. This cluster of CD9 might be an indicator of a higher risk of recurrence, since CD9 plays a role in transendothelial migration (Sauer et al., 2003b). In bladder cancer cell lines GM3 in glycosynapse 3 has a dual functional role. The first one modulates the interaction between α3 integrin and CD9; the second is to activate or inhibit the activity of c-src. Functionally high levels of GM3 reduce motility and invasiveness, while low levels have the opposite effect (Mitsuzuka et al., 2005).
In melanomas CD63, one of the original tetraspanins was identified in melanomas, where its levels inversely correlated with metastatic potential (Hotta et al., 1988), and in cell lines its overexpression suppresses the malignant phenotype (Hotta et al., 1991).
The expression of four tetraspanin proteins, CD9, CD63, CD82 and CD151 was studied in breast carcinoma cell lines with different invasive capabilities in in vitro assays. The expression of three of them, CD9, CD63 and CD151 appeared to be coordinated by a common mechanism, and low levels clearly predicted their invasive potential, particularly for CD63 (Sauer et al., 2003a).
Tetraspanin expression has been studied in a model of colon carcinoma with cell lines derived from primary tumors and two from metastasis. Thirty-two proteins were detected by a proteomic approach and included integrins, proteins with Ig domains, CD44, and epithelial cell adhesion molecule (EpCAM), membrane proteases (ADAM10, TADG-15, and CD26/dipeptidyl peptidase IV), and signaling proteins (heterotrimeric G proteins). Also some differences were identified, particularly the Co-029 tetraspanin antigen in the metastasis, that was almost absent in primary tumors, but very high in normal colon (Le Naour et al., 2006).
In thyroid tumors CD82 is highly expressed in benign goiter, but expression was significantly reduced in carcinomas and were reduced even further in metastasis; in these tumors there were no changes in the expression of CD63 (Chen et al., 2004).
Some prostate carcinomas have downregulated CD9 and CD53 in those cases with high levels of CD151; CD9 and CD53 are upregulated in another group of prostate carcinomas (Lapointe et al., 2004). In these tumors CD9 and CD53 expression seems to be positively coordinated, which is the opposite of what occurs has been detected in other cell types. In low-grade prostate cancer the survival rate was higher in those cases were CD151 levels were lower, and in this study CD151 had a better prediction value than histological (Gleason) grade (Ang et al., 2004). In murine prostate cancer cells can attach to vascular endothelial cells through DARC, and this interaction inhibits proliferation and induces senescence by expression of TBX2 and p21 (Bandyopadhyay et al., 2006). The role of CD82 as a metastasis suppressor is compromised in DARC knockout mice. All these data suggests that the interaction DARC-CD82 is essential for the metastasis suppressor role of CD82 (Bandyopadhyay et al., 2006). It would be interesting to know if a similar interaction is found for other tetraspanin proteins that also behave as metastasis suppressors.
Bladder cancer represents a particular tumor due to its mechanical properties. The expression of uroplakins, an antigen that seals the bladder epithelium, can be used to identify the type of tumors and its severity. Uroplakin II is mainly expressed in transitional bladder carcinomas but not in squamous cell carcinomas and can be use to monitor for circulating cancer cells and in metastasis (Olsburgh et al., 2003).
In breast cancer CD151 is overexpressed in a third of the cases and correlates with high grade, and estrogen receptor negative tumors. The effect of CD151 is mediated by the upregulation of signals by integrin α6 through FAK, Rac1, and lck (Yang et al., 2008).

The future of tetraspanins in cancer biology

Despite the very heterogeneous information on tetraspanin proteins in relation to cancer, it is very likely that patterns of expression of these proteins will affect the behavior of tumor cells with respect to signaling by growth factors, cell motility and sensitivity to therapy, which will be identified when these studies are performed. The regulatory role played by palmitoylation and gangliosides will require further characterization since they modulate cell signaling by associated growth factor receptors. It is expected that in the future these proteins will attract more attention and be studied in the proper context within tumor biology, since they are likely to play an important role in conferring specificity to many biological effects.
Although the basic processes where tetraspanin proteins play a role have already been outlined, their specific participation in these processes and in different cell types will require a systems approach where the multiplicity of components, their relatives levels, and localization are taken simultaneously into account thus generating a specific cell behavior. Their systematic determination in specific tumors is very likely to predict, and/or identify, their metastatic potential.

Bibliography

Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression.
Hotta H, Ross AH, Huebner K, Isobe M, Wendeborn S, Chao MV ,Ricciardi RP, Tsujimoto Y, Croce CM, Koprowski H.
Cancer Res. 1988 Jun 1;48(11):2955-62.
PMID 3365686
 
Transcriptional enhancement of the human gene encoding for a melanoma-associated antigen (ME491) in association with malignant transformation.
Hotta H, Takahashi N, Homma M
Jpn J Cancer Res. 1989 Dec;80(12):1186-91.
PMID 2516848
 
Overexpression of the human melanoma-associated antigen ME491 partially suppresses in vivo malignant phenotypes of H-ras-transformed NIH3T3 cells in athymic nude mice.
Hotta H, Hara I, Miyamoto H, Homma M.
Melanoma Res. 1991 Jun-Jul;1(2):125-32.
PMID 1823625
 
Anti-TAPA-1 antibodies induce protein tyrosine phosphorylation that is prevented by increasing intracellular thiol levels.
Schick MR, Nguyen VQ, Levy S.
J Immunol. 1993 Aug 15;151(4):1918-25.
PMID 7688390
 
Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma.
Si Z, Hersey P.
Int J Cancer. 1993 Apr 22;54(1):37-43.
PMID 8478146
 
Association of four antigens of the tetraspans family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins.
Angelisova P, Hilgert I, Horejsi V.
Immunogenetics. 1994;39(4):249-56.
PMID 8119731
 
Induction of nitric oxide release by MRC OX-44 (anti-CD53) through a protein kinase C-dependent pathway in rat macrophages.
Bosca L, Lazo PA.
J Exp Med. 1994 Apr 1;179(4):1119-26.
PMID 7511680
 
Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin a4/b1 and fibronectin.
Behr S, Schriever F.
J Exp Med. 1995 Nov 1;182(5):1191-9.
PMID 7595190
 
Association of the transmembrane 4 superfamily molecule CD53 with a tyrosine phosphatase activity.
Carmo AM, Wright MD.
Eur J Immunol. 1995 Jul;25(7):2090-5.
PMID 7621882
 
The leukocyte beta 1 integrins.
Hemler ME, Lobb RR.
Curr Opin Hematol. 1995 Jan;2(1):61-7.
PMID 9371973
 
Reduced motility related protein-1 (MRP1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer.
Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, Koh T, Kodama K, Doi O, Miyake M.
Cancer Res. 1995 Dec 15;55(24):6040-4.
PMID 8521390
 
CD82, member of the tetra-span-transmembrane protein family, is a costimulatory protein for T cell activation.
Lebel-Binay S, Lagaudriere C, Fradelizi D, Conjeaud H.
J Immunol. 1995a Jul 1;155(1):101-10.
PMID 7602090
 
CD82, tetra-span-transmembrane protein, is a regulated transducing molecule on U937 monocytic cell line.
Lebel-Binay S, Lagaudriere C, Fradelizi D, Conjeaud H.
J Leukoc Biol. 1995b Jun;57(6):956-63.
PMID 7790779
 
Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491).
Radford KJ, Mallesch J, Hersey P.
Int J Cancer. 1995 Sep 4;62(5):631-5.
PMID 7665237
 
Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.
Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M.
Cancer Res. 1996 Apr 15;56(8):1751-5.
PMID 8620488
 
CD53 antigen and epidermal growth factor induce similar changes in the pattern of phorbol ester binding in a B cell lymphoma.
Barcia R, Garcia-Vargas S, Bosca L, Lazo PA.
Cell Immunol. 1996 Apr 10;169(1):107-12.
PMID 8612282
 
Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins).
Berditchevski F, Zutter MM, Hemler ME.
Mol Biol Cell. 1996 Feb;7(2):193-207.
PMID 8688552
 
Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY.
Szollosi J, Horejsi V, Bene L, Angelisova P, Damjanovich S.
J Immunol. 1996 Oct 1;157(7):2939-46.
PMID 8816400
 
A novel link between integrins, transmembrane-4-superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase.
Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME.
J Biol Chem. 1997 Jan 31;272(5):2595-8.
PMID 9006891
 
Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF activity.
Lagaudriere-Gesbert C, Le Naour F, Lebel-Binay S, Billard M, Lemichez E, Boquet P, Boucheix C, Conjeaud H, Rubinstein E.
Cell Immunol. 1997 Dec 15;182(2):105-12.
PMID 9514697
 
Ligation of CD53/OX44, a tetraspan antigen, induces homotypic adhesion mediated by specific cell-cell interactions.
Lazo PA, Cuevas L, Gutierrez del Arroyo A, Orue E.
Cell Immunol. 1997 Jun 15;178(2):132-40.
PMID 9225004
 
The tetraspanin superfamily: molecular facilitators.
Maecker HT, Todd SC, Levy S.
FASEB J. 1997 May;11(6):428-42.
PMID 9194523
 
Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.
Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M.
Am J Pathol. 1998 Sep;153(3):973-83.
PMID 9736046
 
Signaling through the tetraspanin CD82 triggers its association with the cytoskeleton leading to sustained morphological changes and T cell activation.
Lagaudriere-Gesbert C, Lebel-Binay S, Hubeau C, Fradelizi D, Conjeaud H.
Eur J Immunol. 1998 Dec;28(12):4332-44.
PMID 9862370
 
CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.
Levy S, Todd SC, Maecker HT.
Annu Rev Immunol. 1998;16:89-109.
PMID 9597125
 
Gamma-glutamyl transpeptidase, an ecto-enzyme regulator of intracellular redox potential, is a component of TM4 signal transduction complexes.
Nichols TC, Guthridge JM, Karp DR, Molina H, Fletcher DR, Holers VM.
Eur J Immunol. 1998 Dec;28(12):4123-9.
PMID 9862348
 
Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions.
Yanez-Mo M, Alfranca A, Cabanas C, Marazuela M, Tejedor R, Ursa MA, Ashman LK, de Landazuri MO, Sanchez-Madrid F.
J Cell Biol. 1998 May 4;141(3):791-804.
PMID 9566977
 
Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling.
Berditchevski F, Odintsova E.
J Cell Biol. 1999 Jul 26;146(2):477-92.
PMID 10427099
 
Expression of tetraspans transmembrane family in the epithelium of the gastrointestinal tract.
Okochi H, Mine T, Nashiro K, Suzuki J, Fujita T, Furue M.
J Clin Gastroenterol. 1999 Jul;29(1):63-7.
PMID 10405235
 
Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation.
Ono M, Handa K, Withers DA, Hakomori S.
Cancer Res. 1999 May 15;59(10):2335-9.
PMID 10344740
 
Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma.
Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M, Imamura M.
Br J Cancer. 1999 Mar;79(7-8):1168-73.
PMID 10098753
 
Cell-substrate interactions and signaling through ILK.
Dedhar S.
Curr Opin Cell Biol. 2000 Apr;12(2):250-6.
PMID 10712922
 
Tetraspanins are localized at motility-related structures and involved in normal human keratinocyte wound healing migration.
Penas PF, Garcia-Diez A, Sanchez-Madrid F, Yanez-Mo M.
J Invest Dermatol. 2000 Jun;114(6):1126-35.
PMID 10844555
 
The tetraspanin CD9 associates with transmembrane TGF-alpha and regulates TGF-alpha-induced EGF receptor activation and cell proliferation.
Shi W, Fan H, Shum L, Derynck R.
J Cell Biol. 2000 Feb 7;148(3):591-602.
PMID 10662783
 
The tetraspan molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin alpha6beta4 and may regulate the spatial organization of hemidesmosomes.
Sterk LM, Geuijen CA, Oomen LC, Calafat J, Janssen H, Sonnenberg A.
J Cell Biol. 2000 May 15;149(4):969-82.
PMID 10811835
 
Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis.
Voehringer DW, Hirschberg DL, Xiao J, Lu Q, Roederer M, Lock CB, Herzenberg LA, Steinman L, Herzenberg LA.
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2680-5.
PMID 10716996
 
Direct extracellular contact between integrin alpha(3)beta(1) and TM4SF protein CD151.
Yauch RL, Kazarov AR, Desai B, Lee RT, Hemler ME.
J Biol Chem. 2000 Mar 31;275(13):9230-8.
PMID 10734060
 
Complexes of tetraspanins with integrins: more than meets the eye.
Berditchevski F.
J Cell Sci. 2001 Dec;114(Pt 23):4143-51.
PMID 11739647
 
Tetraspanins.
Boucheix C, Rubinstein E.
Cell Mol Life Sci. 2001 Aug;58(9):1189-205.
PMID 11577978
 
Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts.
Claas C, Stipp CS, Hemler ME.
J Biol Chem. 2001 Mar 16;276(11):7974-84.
PMID 11113129
 
Association of distinct tetraspanins with MHC class II molecules at different subcellular locations in human immature dendritic cells.
Engering A, Pieters J.
Int Immunol. 2001 Feb;13(2):127-34.
PMID 11157846
 
Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis.
Kusukawa J, Ryu F, Kameyama T, Mekada E.
J Oral Pathol Med. 2001 Feb;30(2):73-9.
PMID 11168850
 
Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells.
Longo N, Yanez-Mo M, Mittelbrunn M, de la Rosa G, Munoz ML, Sanchez-Madrid F, Sanchez-Mateos P.
Blood. 2001 Dec 15;98(13):3717-26.
PMID 11739177
 
Structure of the tetraspanin main extracellular domain. A partially conserved fold with a structurally variable domain insertion.
Seigneuret M, Delaguillaumie A, Lagaudriere-Gesbert C, Conjeaud H.
J Biol Chem. 2001 Oct 26;276(43):40055-64. Epub 2001 Aug 1.
PMID 11483611
 
Tetraspanins in intercellular adhesion of polarized epithelial cells: spatial and functional relationship to integrins and cadherins.
Yanez-Mo M, Tejedor R, Rousselle P, Sanchez-Madrid F.
J Cell Sci. 2001 Feb;114(Pt 3):577-87.
PMID 11171326
 
Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(1) integrins.
Zhang XA, Bontrager AL, Hemler ME.
J Biol Chem. 2001 Jul 6;276(27):25005-13.
PMID 11325968
 
Expression of the palmitoylation-deficient CD151 weakens the association of alpha 3 beta 1 integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling.
Berditchevski F, Odintsova E, Sawada S, Gilbert E.
J Biol Chem. 2002 Oct 4;277(40):36991-7000.
PMID 12110679
 
Differential stability of tetraspanin/tetraspanin interactions: role of palmitoylation.
Charrin S, Manie S, Oualid M, Billard M, Boucheix C, Rubinstein E.
FEBS Lett. 2002 Apr 10;516(1-3):139-44.
PMID 11959120
 
Rho GTPases link cytoskeletal rearrangements and activation processes induced via the tetraspanin CD82 in T lymphocytes.
Delaguillaumie A, Lagaudriere-Gesbert C, Popoff MR, Conjeaud H.
J Cell Sci. 2002 Jan 15;115(Pt 2):433-43.
PMID 11839793
 
Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression.
Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC, Davis BJ.
Gynecol Oncol. 2002 Jul;86(1):69-78.
PMID 12079303
 
Distinctive signaling pathways through CD82 and beta1 integrins in human T cells.
Iwata S, Kobayashi H, Miyake-Nishijima R, Sasaki T, Souta-Kuribara A, Nori M, Hosono O, Kawasaki H, Tanaka H, Morimoto C.
Eur J Immunol. 2002 May;32(5):1328-37.
PMID 11981820
 
Tetraspanin CD9 is a "proteolipid," and its interaction with alpha 3 integrin in microdomain is promoted by GM3 ganglioside, leading to inhibition of laminin-5-dependent cell motility.
Kawakami Y, Kawakami K, Steelant WF, Ono M, Baek RC, Handa K, Withers DA, Hakomori S.
Tetraspanin CD9 is a "proteolipid," and its interaction with alpha 3 integrin in microdomain is promoted by GM3 ganglioside, leading to inhibition of laminin-5-dependent cell motility.
PMID 12068006
 
Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells.
Sordat I, Decraene C, Silvestre T, Petermann O, Auffray C, Pietu G, Sordat B.
Lab Invest. 2002 Dec;82(12):1715-24.
PMID 12480921
 
Scatter-factor and semaphorin receptors: cell signalling for invasive growth.
Trusolino L, Comoglio PM.
Nat Rev Cancer. 2002 Apr;2(4):289-300.
PMID 12001990
 
Role of integrins in regulating epidermal adhesion, growth and differentiation.
Watt FM.
EMBO J. 2002 Aug 1;21(15):3919-26.
PMID 12145193
 
The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors.
Yan Y, Shirakabe K, Werb Z.
J Cell Biol. 2002 Jul 22;158(2):221-6.
PMID 12119356
 
Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology.
Yang X, Claas C, Kraeft SK, Chen LB, Wang Z, Kreidberg JA, Hemler ME.
Mol Biol Cell. 2002 Mar;13(3):767-81.
PMID 11907260
 
Transient activation of the c-Jun N-terminal kinase (JNK) activity by ligation of the tetraspan CD53 antigen in different cell types.
Yunta M, Oliva JL, Barcia R, Horejsi V, Angelisova P, Lazo PA.
Eur J Biochem. 2002 Feb;269(3):1012-21.
PMID 11846804
 
A physical and functional link between cholesterol and tetraspanins.
Charrin S, Manie S, Thiele C, Billard M, Gerlier D, Boucheix C, Rubinstein E.
Eur J Immunol. 2003 Sep;33(9):2479-89.
PMID 12938224
 
Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray.
Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks JD.
Am J Pathol. 2003 Mar;162(3):925-32.
PMID 12598325
 
Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.
Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G, Poulsom R, Selby P, Southgate J.
J Pathol. 2003 Jan;199(1):41-9.
PMID 12474225
 
Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells.
Sauer G, Kurzeder C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H.
Oncol Rep. 2003a Mar-Apr;10(2):405-10.
PMID 12579280
 
Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion.
Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R, Deissler H.
Clin Cancer Res. 2003b Dec 15;9(17):6426-31.
PMID 14695144
 
CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization.
Shigeta M, Sanzen N, Ozawa M, Gu J, Hasegawa H, Sekiguchi K.
J Cell Biol. 2003 Oct 13;163(1):165-76.
PMID 14557253
 
Functional domains in tetraspanin proteins.
Stipp CS, Kolesnikova TV, Hemler ME.
Trends Biochem Sci. 2003 Feb;28(2):106-12.
PMID 12575999
 
Tetraspanins: molecular organisers of the leukocyte surface.
Tarrant JM, Robb L, van Spriel AB, Wright MD.
Trends Immunol. 2003 Nov;24(11):610-7.
PMID 14596886
 
Apoptosis protection and survival signal by the CD53 tetraspanin antigen.
Yunta M, Lazo PA.
Oncogene. 2003 Feb 27;22(8):1219-24.
PMID 12606948
 
Induction of DNA synthesis by ligation of the CD53 tetraspanin antigen in primary cultures of mesangial cells.
Yunta M, Rodriguez-Barbero A, Arevalo MA, Lopez-Novoa JM, Lazo PA.
Kidney Int. 2003 Feb;63(2):534-42.
PMID 12631118
 
Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration.
Zhang XA, He B, Zhou B, Liu L.
J Biol Chem. 2003 Jul 18;278(29):27319-28.
PMID 12738793
 
CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator?
Ang J, Lijovic M, Ashman LK, Kan K, Frauman AG.
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1717-21.
PMID 15533898
 
CD82, and CD63 in thyroid cancer.
Chen Z, Mustafa T, Trojanowicz B, Brauckhoff M, Gimm O, Schmutzler C, Kohrle J, Holzhausen HJ, Kehlen A, Klonisch T, Finke R, Dralle H, Hoang-Vu C.
Int J Mol Med. 2004 Oct;14(4):517-27.
PMID 15375577
 
B cell signaling is regulated by induced palmitoylation of CD81.
Cherukuri A, Carter RH, Brooks S, Bornmann W, Finn R, Dowd CS, Pierce SK.
J Biol Chem. 2004 Jul 23;279(30):31973-82.
PMID 15161911
 
CD81 associates with 14-3-3 in a redox-regulated palmitoylation-dependent manner.
Clark KL, Oelke A, Johnson ME, Eilert KD, Simpson PC, Todd SC.
J Biol Chem. 2004 May 7;279(19):19401-6.
PMID 14966136
 
Tetraspanin CD82 controls the association of cholesterol-dependent microdomains with the actin cytoskeleton in T lymphocytes: relevance to co-stimulation.
Delaguillaumie A, Harriague J, Kohanna S, Bismuth G, Rubinstein E, Seigneuret M, Conjeaud H.
J Cell Sci. 2004 Oct 15;117(Pt 22):5269-82.
PMID 15454569
 
CD9 expression in gastric cancer and its significance.
Hori H, Yano S, Koufuji K, Takeda J, Shirouzu K.
J Surg Res. 2004 Apr;117(2):208-15.
PMID 15047125
 
Evidence for specific tetraspanin homodimers: inhibition of palmitoylation makes cysteine residues available for cross-linking.
Kovalenko OV, Yang X, Kolesnikova TV, Hemler ME.
Biochem J. 2004 Jan 15;377(Pt 2):407-17.
PMID 14556650
 
Gene expression profiling identifies clinically relevant subtypes of prostate cancer.
Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR.
Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6.
PMID 14711987
 
Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside).
Miura Y, Kainuma M, Jiang H, Velasco H, Vogt PK, Hakomori S.
Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16204-9.
PMID 15534203
 
Cell growth regulation through GM3-enriched microdomain (glycosynapse) in human lung embryonal fibroblast WI38 and its oncogenic transformant VA13.
Toledo MS, Suzuki E, Handa K, Hakomori S.
J Biol Chem. 2004 Aug 13;279(33):34655-64.
PMID 15143068
 
Tetraspanin microdomains in immune cell signalling and malignant disease.
Wright MD, Moseley GW, van Spriel AB.
Tissue Antigens. 2004 Nov;64(5):533-42.
PMID 15496196
 
Palmitoylation supports assembly and function of integrin-tetraspanin complexes.
Yang X, Kovalenko OV, Tang W, Claas C, Stipp CS, Hemler ME.
J Cell Biol. 2004 Dec 20;167(6):1231-40.
PMID 15611341
 
The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activity.
Zhou B, Liu L, Reddivari M, Zhang XA.
Cancer Res. 2004 Oct 15;64(20):7455-63.
PMID 15492270
 
Discrimination of biclonal B-cell chronic lymphoproliferative neoplasias by tetraspanin antigen expression.
Barrena S, Almeida J, Yunta M, Lopez A, Diaz-Mediavilla J, Orfao A, Lazo PA.
Leukemia. 2005a Sep;19(9):1708-9.
PMID 15973446
 
Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation.
Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M, Romero M, Perdiguer L, Delgado M, Orfao A, Lazo PA.
Leukemia. 2005b Aug;19(8):1376-83.
PMID 15931266
 
Role of tetraspanins CD9 and CD151 in primary melanocyte motility.
Garcia-Lopez MA, Barreiro O, Garcia-Diez A, Sanchez-Madrid F, Penas PF.
J Invest Dermatol. 2005 Nov;125(5):1001-9.
PMID 16297202
 
Tetraspanin functions and associated microdomains.
Hemler ME.
Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11.
PMID 16314869
 
Protein-protein interactions in the tetraspanin web.
Levy S, Shoham T.
Physiology (Bethesda). 2005 Aug;20:218-24.
PMID 16024509
 
A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.
Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S.
J Biol Chem. 2005 Oct 21;280(42):35545-53.
PMID 16103120
 
Potentiation of the ligand-binding activity of integrin alpha3beta1 via association with tetraspanin CD151.
Nishiuchi R, Sanzen N, Nada S, Sumida Y, Wada Y, Okada M, Takagi J, Hasegawa H, Sekiguchi K.
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1939-44.
PMID 15677332
 
Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression.
Bandyopadhyay S, Zhan R, Chaudhuri A, Watabe M, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y, Saito K, Pauza ME, Hayashi S, Wang Y, Mohinta S, Mashimo T, Iiizumi M, Furuta E, Watabe K.
Nat Med. 2006 Aug;12(8):933-8.
PMID 16862154
 
Dissociation of the complex between CD151 and laminin-binding integrins permits migration of epithelial cells.
Chometon G, Zhang ZG, Rubinstein E, Boucheix C, Mauch C, Aumailley M.
Exp Cell Res. 2006 Apr 15;312(7):983-95.
PMID 16490193
 
Homophilic interactions of Tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways.
Hong IK, Jin YJ, Byun HJ, Jeoung DI, Kim YM, Lee H.
J Biol Chem. 2006 Aug 25;281(34):24279-92.
PMID 16798740
 
New roles for integrins in squamous-cell carcinoma.
Janes SM, Watt FM.
Nat Rev Cancer. 2006 Mar;6(3):175-83.
PMID 16498442
 
Syntenin-1 is a new component of tetraspanin-enriched microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63.
Latysheva N, Muratov G, Rajesh S, Padgett M, Hotchin NA, Overduin M, Berditchevski F.
Mol Cell Biol. 2006 Oct;26(20):7707-18.
PMID 16908530
 
Profiling of the tetraspanin web of human colon cancer cells.
Le Naour F, Andre M, Greco C, Billard M, Sordat B, Emile JF, Lanza F, Boucheix C, Rubinstein E.
Mol Cell Proteomics. 2006 May;5(5):845-57.
PMID 16467180
 
Gangliosides play an important role in the organization of CD82-enriched microdomains.
Odintsova E, Butters TD, Monti E, Sprong H, van Meer G, Berditchevski F.
Biochem J. 2006 Dec 1;400(2):315-25.
PMID 16859490
 
EWI-2 and EWI-F link the tetraspanin web to the actin cytoskeleton through their direct association with ezrin-radixin-moesin proteins.
Sala-Valdes M, Ursa A, Charrin S, Rubinstein E, Hemler ME, Sanchez-Madrid F, Yanez-Mo M.
J Biol Chem. 2006 Jul 14;281(28):19665-75. Epub 2006 May 10.
PMID 16690612
 
Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments.
Shoham T, Rajapaksa R, Kuo CC, Haimovich J, Levy S.
Mol Cell Biol. 2006 Feb;26(4):1373-85.
PMID 16449649
 
Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases.
Sridhar SC, Miranti CK.
Oncogene. 2006 Apr 13;25(16):2367-78.
PMID 16331263
 
A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5.
Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS.
Mol Biol Cell. 2006 Jun;17(6):2707-21.
PMID 16571677
 
Contrasting effects of EWI proteins, integrins, and protein palmitoylation on cell surface CD9 organization.
Yang XH, Kovalenko OV, Kolesnikova TV, Andzelm MM, Rubinstein E, Strominger JL, Hemler ME.
J Biol Chem. 2006 May 5;281(18):12976-85.
PMID 16537545
 
Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins.
Beckmann J, Scheitza S, Wernet P, Fischer JC, Giebel B.
Blood. 2007 Jun 15;109(12):5494-501.
PMID 17332245
 
Tetraspanins as regulators of protein trafficking.
Berditchevski F, Odintsova E.
Traffic. 2007 Feb;8(2):89-96.
PMID 17181773
 
Basal cells of the human adult airway surface epithelium retain transit-amplifying cell properties.
Hajj R, Baranek T, Le Naour R, Lesimple P, Puchelle E, Coraux C.
Stem Cells. 2007 Jan;25(1):139-48.
PMID 17008423
 
Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression.
Iiizumi M, Bandyopadhyay S, Watabe K.
Cancer Res. 2007 Feb 15;67(4):1411-4.
PMID 17308076
 
Functional implications of tetraspanin proteins in cancer biology.
Lazo PA.
Cancer Sci. 2007 Nov;98(11):1666-77.
PMID 17727684
 
Shed gangliosides provide detergent-independent evidence for type-3 glycosynapses.
Thorne RF, Mhaidat NM, Ralston KJ, Burns GF.
Biochem Biophys Res Commun. 2007 Apr 27;356(1):306-11.
PMID 17350595
 
Ganglioside GM2-tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse.
Todeschini AR, Dos Santos JN, Handa K, Hakomori SI.
J Biol Chem. 2007 Mar 16;282(11):8123-33.
PMID 17215249
 
Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential.
Tohami T, Drucker L, Shapiro H, Radnay J, Lishner M.
FASEB J. 2007 Mar;21(3):691-9.
PMID 17210782
 
The tetraspanin CD9 mediates lateral association of MHC class II molecules on the dendritic cell surface.
Unternaehrer JJ, Chow A, Pypaert M, Inaba K, Mellman I.
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):234-9.
PMID 17190803
 
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I.
Clin Cancer Res. 2008 May 15;14(10):2918-26.
PMID 18483358
 
Ganglioside GM2/GM3 complex affixed on silica nanospheres strongly inhibits cell motility through CD82/cMet-mediated pathway.
Todeschini AR, Dos Santos JN, Handa K, Hakomori SI.
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1925-30.
PMID 18272501
 
The tetraspanin CD151 regulates cell morphology and intracellular signaling on laminin-511.
Yamada M, Sumida Y, Fujibayashi A, Fukaguchi K, Sanzen N, Nishiuchi R, Sekiguchi K.
FEBS J. 2008 Jul;275(13):3335-51.
PMID 18492066
 
CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization.
Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, Andzelm MM, Strominger JL, Brown M, Hemler ME.
Cancer Res. 2008 May 1;68(9):3204-13.
PMID 18451146
 
The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151.
Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP.
Cancer Cell. 2008 Mar;13(3):221-34.
PMID 18328426
 

Contributor(s)

Written09-2008Pedro A Lazo
Programa de Oncología Translacional, Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Salamanca, E-37007, Spain

Citation

This paper should be referenced as such :
Lazo PA . Roles of tetraspanin proteins in cell and tumor biology. Atlas Genet Cytogenet Oncol Haematol. September 2008 .
URL : http://AtlasGeneticsOncology.org/Deep/TetraspaninID20062.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sat Oct 18 16:42:11 2008

Home   Genes    Leukemias    Solid Tumours    Cancer-Prone    Deep Insight    Case Reports    Journals   Portal    Teaching   
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

For comments and suggestions or contributions, please contact us

j.l.huret@chu-poitiers.fr.